

Canserv – providing cutting edge cancer research services across europe

Abstract Submitter: Jens K. Habermann, Austria*

Co-Authors: Manuela Pausan, John Eriksson, Serena Scollen, Vitor Martins dos Santos, Enzo Medico, Bahne Stechmann, Michael Hagn, Corinna Brockhaus, Stéphane Lejeune, Zisis Kozlakidis, Michael Raess, Nicolas Pade, Marta del Alamo, Elena Garralda, Emanuela Oldoni

*BBMRI-ERIC

Abstract

Background: canSERV is a € 15 Mio. project offering cutting-edge research services, enabling innovative R&D projects and fostering precision medicine for patients benefit. canSERV involves 18 leading organizations across Europe including Research Infrastructures, key organisations and oncology experts.

Objectives: canSERV's main objectives are: (i) offer at least 200 different unique Personalised Oncology relevant and valuable cutting-edge services; (ii) establish a single, unified, transnational access platform to request services and trainings; (iii) ensure oncology-related data provided will be fully compliant with FAIR principles and complement and synergise with other EU initiatives and (iv) ensure long-term sustainability beyond project duration. Furthermore, canSERV establishes the European Molecular Tumour Board Network (EMTBN) that is open for anyone to join. The EMTBN develops Molecular Tumour Board (MTB) consensus guidelines, an MTB outcome registry, and provides advice to scientists, clinicians, and MTBs.

Results: canSERV offers a series of open and challenge calls for access to services in the amount of ~ € 9 Mio. The calls are designed to support researchers to develop innovative research projects that explore cutting-edge methodologies and target critical gaps in cancer research and care by providing funding to services. Over the past two years, canSERV launched 3 open calls and 4 challenge calls that resulted in 336 research proposals submissions from 41 countries worldwide. These proposals address a diverse array of important frontiers in cancer research, including biomarker discovery and validation, novel therapeutics, advanced diagnostics, understanding cancer biology, cutting-edge AI/ML models for oncology and the advancement of precision medicine.

Conclusions: canSERV presents an unparalleled opportunity to accelerate cancer research, drive innovation, and improve patient outcomes. canSERV is granted by the EU Horizon programme under #101058620.

Do you have any conflicts of interest?

No, I do not have a conflict of interest.